Practice Test Geeks(FRACGP) Fellowship of the Royal Australian College of General Practitioners Practice Test
← All FRACGP Flashcard Decks

Chronic Disease Management Flashcards

7 cards from real FRACGP practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.

Read the first 7 Chronic Disease Management flashcards as text

  1. Which HbA1c target is generally recommended for most adults with type 2 diabetes in Australian general practice?

    Answer: Less than 7.0%

    An HbA1c of less than 7.0% (53 mmol/mol) is the standard target for most adults with type 2 diabetes, balancing glycaemic control with minimising hypoglycaemia risk.

  2. A 65-year-old patient with hypertension and chronic kidney disease (eGFR 45 mL/min/1.73m²) presents for medication review. Which antihypertensive class is most recommended as first-line in this scenario?

    Answer: ACE inhibitor or ARB

    ACE inhibitors and ARBs are preferred in patients with CKD and hypertension due to their nephroprotective effects and reduction in proteinuria progression.

  3. According to COPD management guidelines, which intervention has the greatest evidence for reducing mortality in patients with severe COPD and resting hypoxaemia?

    Answer: Long-term oxygen therapy

    Long-term oxygen therapy (LTOT) for ≥15 hours/day has the strongest evidence for reducing mortality in COPD patients with resting hypoxaemia (PaO2 ≤55 mmHg).

  4. A patient with established cardiovascular disease is commenced on a statin. What is the primary LDL-cholesterol target recommended in Australian guidelines?

    Answer: Less than 1.8 mmol/L

    For patients with established cardiovascular disease (secondary prevention), Australian guidelines recommend an LDL-C target of less than 1.8 mmol/L.

  5. Which medication used in heart failure management has been shown to reduce both hospitalisation and mortality and belongs to the SGLT2 inhibitor class?

    Answer: Empagliflozin

    Empagliflozin (an SGLT2 inhibitor) has demonstrated significant reductions in heart failure hospitalisation and cardiovascular mortality in the EMPEROR-Reduced and EMPEROR-Preserved trials.

  6. In managing a patient with asthma, when should a preventer inhaler (inhaled corticosteroid) be initiated?

    Answer: When reliever use exceeds 2 days per week

    Preventer therapy should be initiated when reliever (SABA) use is required more than twice per week, indicating uncontrolled asthma that needs regular anti-inflammatory treatment.

  7. A patient with osteoarthritis of the knee has failed paracetamol therapy. Which is the most appropriate next pharmacological step according to evidence-based guidelines?

    Answer: Topical or oral NSAIDs

    Topical NSAIDs (preferred for localised knee OA) or oral NSAIDs are recommended as the next step after paracetamol failure, given their anti-inflammatory efficacy with lower systemic risk for topical preparations.